Open Angle GlaucomaNCT06851546
Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree
A study testing Nasal 180° Selective Laser Trabeculoplasty (SLT) and Inferior 180° Selective Laser Trabeculoplasty (SLT) in people with Open Angle Glaucoma, run by Mayo Clinic at 2 sites in 2 countries.
Trial summary
The purpose of this study to optimize Selective Laser Trabeculoplasty (SLT) application when used in the management of open angle glaucoma (OAG) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Open Angle Glaucoma
- What is being tested?
- Nasal 180° Selective Laser Trabeculoplasty (SLT) and Inferior 180° Selective Laser Trabeculoplasty (SLT)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 6 Jan 2025to 10 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years and older
- Ability to comprehend the study procedures and agreement to proceed with primary SLT treatment
- Diagnosis of primary or secondary open angle glaucoma or glaucoma suspects with ocular hypertension
- Bilateral disease
- Pre-SLT IOP >21 mmHg measured at least twice during patient's lifetime with or without medication
- Open angles with moderate to intense trabecular pigmentation
- Mild to moderate visual field defects (24-2 standard mean deviations better than the Swedish interactive thresholding algorithm standard of 12 dB)
- No adequate IOP control (low treatment compliance, substantial adverse effects with eyedrops, and at least 2 IOP measurements higher than the individualized target IOP)
Who cannot join
- Unwilling or unable to give consent
- Unable to attend scheduled post-operative visits
- Previous history of either laser treatment or intraocular surgery, except for non-complicated cataract surgery (performed >6 months before SLT)
- History of ocular trauma
- Narrow angles
- Retinal detachment
Show all 10Show fewer
- Active iris neovascularization or active proliferative retinopathy
- Active uveitis
- Monocular patients
- Current use of steroids (ocular, periocular, or systemic)
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
United States1 site
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Canada1 site
Eye Care Centre, Victoria General Hospital
Halifax, Nova Scotia, NS B3H 2Y9
About this study
The purpose of this study to optimize Selective Laser Trabeculoplasty (SLT) application when used in the management of open angle glaucoma (OAG)
Read the detailed description
The purpose of this research is to determine the most effective method in using Selective Laser Trabeculoplasty (SLT) for lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. We will investigate the IOP lowering differences between nasal 180° SLT and inferior 180° SLT,. The second stage will assess the effect of repeating SLT in the opposite 180° sector after 3 months.
- Conditions
- Open Angle Glaucoma
- Being tested
- Nasal 180° Selective Laser Trabeculoplasty (SLT), Inferior 180° Selective Laser Trabeculoplasty (SLT)
- Medical subject headings
- Glaucoma, Open-Angle
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nasal 180° Selective Laser Trabeculoplasty (SLT)Procedure or surgery
The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
Inferior 180° Selective Laser Trabeculoplasty (SLT)Procedure or surgery
The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
| Study group | Role | What they receive |
|---|---|---|
| Nasal 180° Selective Laser Trabeculoplasty (SLT) | Experimental | The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye.
After 90 days, the Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. Receives: Procedure: Nasal 180° Selective Laser Trabeculoplasty (SLT); Procedure: Inferior 180° Selective Laser Trabeculoplasty (SLT) |
| Inferior 180° Selective Laser Trabeculoplasty (SLT) | Experimental | The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye.
After 90 days, the Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. Receives: Procedure: Nasal 180° Selective Laser Trabeculoplasty (SLT); Procedure: Inferior 180° Selective Laser Trabeculoplasty (SLT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in mean intraocular pressure (IOP)
During each visit, two consecutive IOP measurements will be obtained per eye, and the average of these values will be reported.
Measured: Baseline, 3 months, 6 months, 9 months
Secondary outcomes (2)
Change in intraocular pressure (IOP)
Change in intraocular pressure (IOP), reported as a percentage
Measured: Baseline, 3 months, 6 months, 9 months
Intraocular pressure (IOP) lowering eye drops
Total number of patients that did not need intraocular pressure (IOP) lowering drops after the selective laser trabeculoplasty (SLT)
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2025
- Study start6 Jan 2025
- Primary completion10 Nov 2025
- Study completion10 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Open Angle GlaucomaStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Arthur J. Sit, M.D., Mayo Clinic
- Investigators
- Arthur Sit, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06851546
- Sponsor's protocol ID
- 24-008197
- Status last verified
- Jan 2026
- First submitted
- 24 Feb 2025
- Last updated
- 7 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree
- ClinicalTrials.gov ID
- NCT06851546
- Acronym / sponsor ID
- 24-008197
- Conditions
- Open Angle Glaucoma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 6 Jan 2025 (actual)
- Primary completion
- 10 Nov 2025 (actual)
- Study completion
- 10 Nov 2025 (actual)
- First posted
- 28 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study to optimize Selective Laser Trabeculoplasty (SLT) application when used in the management of open angle glaucoma (OAG)
Detailed description
The purpose of this research is to determine the most effective method in using Selective Laser Trabeculoplasty (SLT) for lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. We will investigate the IOP lowering differences between nasal 180° SLT and inferior 180° SLT,. The second stage will assess the effect of repeating SLT in the opposite 180° sector after 3 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nasal 180° Selective Laser Trabeculoplasty (SLT) | Experimental | Procedure: Nasal 180° Selective Laser Trabeculoplasty (SLT), Procedure: Inferior 180° Selective Laser Trabeculoplasty (SLT)The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. After 90 days, the Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. |
| Inferior 180° Selective Laser Trabeculoplasty (SLT) | Experimental | Procedure: Nasal 180° Selective Laser Trabeculoplasty (SLT), Procedure: Inferior 180° Selective Laser Trabeculoplasty (SLT)The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. After 90 days, the Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age 18 years and older
- Ability to comprehend the study procedures and agreement to proceed with primary SLT treatment
- Diagnosis of primary or secondary open angle glaucoma or glaucoma suspects with ocular hypertension
- Bilateral disease
- Pre-SLT IOP >21 mmHg measured at least twice during patient's lifetime with or without medication
Key exclusion criteria (10 listed)
- Unwilling or unable to give consent
- Unable to attend scheduled post-operative visits
- Previous history of either laser treatment or intraocular surgery, except for non-complicated cataract surgery (performed >6 months before SLT)
- History of ocular trauma
- Narrow angles
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nasal 180° Selective Laser Trabeculoplasty (SLT)The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference. | Procedure or surgery | Inferior 180° Selective Laser Trabeculoplasty (SLT), Nasal 180° Selective Laser Trabeculoplasty (SLT) |
| Inferior 180° Selective Laser Trabeculoplasty (SLT)The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference. | Procedure or surgery | Inferior 180° Selective Laser Trabeculoplasty (SLT), Nasal 180° Selective Laser Trabeculoplasty (SLT) |
Primary outcome
Difference in mean intraocular pressure (IOP)
Time frame: Baseline, 3 months, 6 months, 9 months
During each visit, two consecutive IOP measurements will be obtained per eye, and the average of these values will be reported.
2 secondary outcomes
Change in intraocular pressure (IOP)
Time frame: Baseline, 3 months, 6 months, 9 months
Intraocular pressure (IOP) lowering eye drops
Time frame: 9 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Open Angle Glaucoma
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Recruiting
The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
Glaucoma Open-Angle Primary, Hypertension
RecruitingPhase 4
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Open Angle Glaucoma (OAG), Glaucoma
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arthur Sit principal investigator
Mayo Clinic
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nasal 180° Selective Laser Trabeculoplasty (SLT) and Inferior 180° Selective Laser Trabeculoplasty (SLT) in people with Open Angle Glaucoma, run by Mayo Clinic at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in mean intraocular pressure (IOP) (time frame: Baseline, 3 months, 6 months, 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.